ArticleBMC microbiology2026
Hypolipidemic activity of Limosilactobacillus fermentum SHY0004 from Miao sour soup.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundProbiotics have been demonstrated to regulate metabolic homeostasis through multiple mechanisms. Miao sour soup, a traditional fermented food from Guizhou Province, contains diverse beneficial microorganisms with potential physiological activities; however, its hypolipidemic function has not yet been fully explored. This study aims to isolate and identify edible lactic acid bacteria (LAB) with defined hypolipidemic activity from Miao sour soup, providing new microbial resources for the development of functional probiotics.
resultsA lactic acid bacterium consistent with the List of Edible Microorganisms was isolated and purified from Miao sour soup and identified as Limosilactobacillus fermentum SHY0004. Functional evaluation showed that this strain exhibited feruloyl esterase activity and demonstrated significant hypolipidemic effects in both the high-fat-induced HepG2 cell model and the high-fat zebrafish model. In the high-fat diet (HFD) mice experiment, SHY0004 effectively regulated total cholesterol (TC) and triglyceride (TG) levels in serum and liver, resulting in a clear lipid-lowering effect.
conclusionsSHY0004 demonstrates hypolipidemic activity across multiple experimental models, providing experimental evidence for the functional potential of Miao sour soup. This strain shows promising application prospects for the development of functional foods or nutraceuticals aimed at preventing or managing hyperlipidemia, fatty liver, and obesity-related metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.